Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma

被引：3
作者：
Fenk, R
Hoyer, B
Steidl, U
Kondakci, M
Graef, T
Heuk, R
Ruf, L
Strupp, C
Neumann, F
Rohr, UP
Hildebrandt, B
Haas, R
Kobbe, G
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany
[2] Harvard Univ, Inst Med, Div Hematol Oncol, Boston, MA 02115 USA
[3] Univ Dusseldorf, Dept Human Genet & Anthropol, D-40225 Dusseldorf, Germany
来源：
LEUKEMIA | 2005年 / 19卷 / 01期
关键词：
D O I：
10.1038/sj.leu.2403564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：156 / 159
页数：5
相关论文
共 10 条
  • [1] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
    Barlogie, B
    Desikan, R
    Eddlemon, P
    Spencer, T
    Zeldis, J
    Munshi, N
    Badros, A
    Zangari, M
    Anaissie, E
    Epstein, J
    Shaughnessy, J
    Ayers, D
    Spoon, D
    Tricot, G
    [J]. BLOOD, 2001, 98 (02) : 492 - 494
  • [2] Thalidomide in multiple myeloma: Current status and future prospects
    Cavenagh, JD
    Oakervee, H
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) : 18 - 26
  • [3] Treatment of plasma cell dyserasias with thalidomide and its derivatives
    Dimopoulos, MA
    Anagnostopoulos, A
    Weber, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4444 - 4454
  • [4] Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
    Kropff, MH
    Lang, N
    Bisping, G
    Dominé, N
    Innig, G
    Hentrich, M
    Mitterer, M
    Südhoff, T
    Fenk, R
    Straka, C
    Heinecke, A
    Koch, OM
    Ostermann, H
    Berdel, WE
    Kienast, J
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) : 607 - 616
  • [5] Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Kumar, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Geyer, SM
    Iturria, NL
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, RA
    Greipp, PR
    Witzig, TE
    Rajkumar, SV
    [J]. MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 34 - 39
  • [6] Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
    Mileshkin, L
    Biagi, JJ
    Mitchell, P
    Underhill, C
    Grigg, A
    Bell, R
    McKendrick, J
    Briggs, P
    Seymour, JF
    Lillie, K
    Smith, JG
    Zeldis, JB
    Prince, HM
    [J]. BLOOD, 2003, 102 (01) : 69 - 77
  • [7] Neben K, 2002, CLIN CANCER RES, V8, P3377
  • [8] Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
    Palumbo, A
    Bertola, A
    Falco, P
    Rosato, R
    Cavallo, F
    Giaccone, L
    Bringhen, S
    Musto, P
    Pregno, P
    Caravita, T
    Ciccone, G
    Boccadoro, M
    [J]. HEMATOLOGY JOURNAL, 2004, 5 (04) : 318 - 324
  • [9] An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment
    Schey, SA
    Cavenagh, J
    Johnson, R
    Child, JA
    Oakervee, H
    Jones, RW
    [J]. LEUKEMIA RESEARCH, 2003, 27 (10) : 909 - 914
  • [10] Yakoub-Agha Ibrahim, 2002, Hematol J, V3, P185, DOI 10.1038/sj.thj.6200175
1